(Alliance News) - Abcam PLC said Thursday the completed purchase of Expedeon AG's proteomics and immunology businesses for EUR120 million positions Abcam well for growth.
Alan Hirzel, chief executive officer of the life science research tools supplier, said: "Expedeon's portfolio of products and technology, combined with Abcam's antibody and protein strengths, place us well to address the growing need for antibody conjugation and multiplexing solutions."
Abcam said the acquisition "secures a complementary portfolio of leading protein conjugation technologies and products", such as " well-known industry brands Lightning-Link and CaptSure".
Shares in Abcam were up 1.3% at 1,369.00 pence in London on Thursday morning.
The deal was announced November 11 and will see Expedeon change its name to 4basebio AG as it shifts focus towards DNA manufacturing and enzymes for diagnostics. It intends to supply DNA products for use in, for example, gene therapy and gene vaccines.
Of the EUR120 million due to Expedeon, EUR105.6 million will be paid immediately with the other EUR14.4 million held in escrow for another two years.
Expedeon CEO Heikki Lanckriet said: "We are now commencing a new chapter in the company's development with a new name, a new business focus and excellent funding resulting from this transaction. Referring to the four base building blocks of all genetic material, the new company name 4basebio reflects our new DNA-based business focus. We will also continue with our successful buy and build strategy."
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
